Stanley Druckenmiller's ADMA Position Overview
Stanley Druckenmiller (via Duquesne Family Office LLC) currently holds 1.55 M shares of ADMA Biologics, Inc. (ADMA) worth $13.93 M, representing 0.41% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Stanley Druckenmiller has initiated a new position in ADMA, representing a fresh investment thesis on this company. Largest addition occurred in Q1 2026, adding 1.29 M shares.
Analysis based on 13F filings available since 2013 Q2
Stanley Druckenmiller's ADMA Biologics (ADMA) Holding Value Over Time
Track share changes against reported price movement
Quarterly ADMA Biologics (ADMA) Trades by Stanley Druckenmiller
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +1.29 M | Add 512.85% | 1.55 M | $9.01 |
| Q4 2025 | +252,200 | New Buy | 252,200 | $18.24 |
Stanley Druckenmiller's ADMA Biologics Investment FAQs
Stanley Druckenmiller first purchased ADMA Biologics, Inc. (ADMA) in Q4 2025, acquiring 252,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Stanley Druckenmiller has held ADMA Biologics, Inc. (ADMA) for 2 quarters since Q4 2025.
Stanley Druckenmiller's largest addition to ADMA Biologics, Inc. (ADMA) was in Q1 2026, adding 1,545,610 shares worth $13.93 M.
According to the latest 13F filing for Q1 2026, Stanley Druckenmiller's firm, Duquesne Family Office LLC, owns 1,545,610 shares of ADMA Biologics, Inc. (ADMA), valued at approximately $13.93 M.
As of the Q1 2026 filing, ADMA Biologics, Inc. (ADMA) represents approximately 0.41% of Stanley Druckenmiller's publicly disclosed stock portfolio, making it one of their key holdings.
Stanley Druckenmiller's peak holding in ADMA Biologics, Inc. (ADMA) was 1,545,610 shares, as reported at the end of Q1 2026.